Loading quotes...

Forecast

The analysts' average price target is €9.91 (+692.80%). The median is €4.43 (+254.40%).

Buy	11
Hold	0
Sell	0

News Go to news feed

Actinium shows strong preclinical efficacy of ATNM-400 in NSCLC models

Actinium presented preclinical data on ATNM-400, an Actinium-225–linked radioconjugate for non‑small cell lung cancer, at the Society of Nuclear Medicine annual meeting. In KRAS‑mutant models, ATNM-400 as monotherapy outperformed the KRAS inhibitors sotorasib and adagrasib and enhanced their tumor‑cell killing when combined. In EGFR‑mutant models, ATNM-400 achieved 75% tumor growth inhibition versus 40% for osimertinib; the combination produced complete tumor regressions in all treated mice. The target antigen was detectable in approximately 98% of NSCLC tumors, and investor assessments see upside potential for the stock despite high cash burn. » More on de.investing.com
Actinium presents preclinical data on ATNM-400 and Actimab‑A at AACR on April 21

Actinium will present posters with unpublished preclinical data on April 21 at the AACR annual meeting for ATNM-400 (an Ac‑225 radioconjugate for solid tumors) and Actimab‑A (a therapy for AML/MDS). ATNM-400 showed activity in models of metastatic, castration‑resistant prostate cancer as well as non‑small cell lung and breast cancer; Actimab‑A data illuminate a mechanism described as “transcriptional reprogramming.” The presentations are part of the session block “Radiopharmaceutical Platforms for Theranostic Precision Oncology”; Actimab‑A is being co‑developed with the National Cancer Institute. The stock is trading near its 52‑week low and the company reports high liquidity. » More on de.investing.com
Actinium Pharmaceuticals rises after promising preclinical data on ATNM-400

Actinium Pharmaceuticals' stock rose about 3.7% after the presentation of new preclinical data on ATNM-400 at the San Antonio Breast Cancer Symposium 2025. The Actinium-225–based antibody‑radioconjugate showed strong antitumor activity in several breast cancer models, including hormone receptor‑positive, triple‑negative and treatment‑resistant tumors, with a favorable tolerability profile. The data demonstrated irreversible double‑strand DNA breaks caused by the alpha‑emitter payload; Actinium plans to advance ATNM-400 as a monotherapy and in combinations and sees potential also in prostate and non‑small‑cell lung cancer. » More on de.investing.com

Financials

In the last quarter, Actinium Pharmaceuticals had revenue of €30.67M and net profit of €24.45M

(EUR)	June 2026	YoY
Revenue	30.67M	-
Gross profit	30.67M	-
Net profit	24.45M	518.94%
EBITDA	24.66M	535.48%

Fundamentals

Metric	Value
Market capitalization	€42.77M
Number of shares	31.44M
52-week high/low	€1.54 - €0.66
Dividends	No
Beta	0.02
P/E ratio	4.22
PEG ratio	0.01
P/B ratio	1.58
P/S ratio	1.36

Company profile

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.